Kristine M. Ball
Independent DirectorMs. Kristine M. Ball, C.P.A., serves as Director at Enliven Therapeutics, Inc. since October 14, 2026. Ms. Ball has many years of executive experience across clinical-stage and commercial-stage biopharmaceutical companies. Ms. Ball brings extensive executive leadership and financial expertise in the biotechnology industry. Her experience spans corporate strategy, financing, commercial readiness and corporate governance. She is Chief Executive Officer, President and Director of Antiva Biosciences, Inc. since April 2023. She joined Soteria Biotherapeutics, Inc. in 2020. She served as Former CEO, CFO, Secretary & Director of Soteria Biotherapeutics, Inc. She is Independent Director of Oruka Therapeutics, Inc since May 2024. Ms. Ball served as Senior Vice President of Corporate Strategy and Chief Financial Officer at Menlo Therapeutics Inc. since September 2017 until March 2020. Ms. Ball served as an Independent Director at Atreca, Inc. since May 2020. Ms. Ball served as Chief Financial Officer and Senior Vice President of Relypsa, Inc. since November 2012 until October 2016 and served its Principal Accounting Officer until October 2017. Ms. Ball has many of experience in finance and accounting in the life science industry in both in-house and public accounting roles and has extensive experience in finance, strategy and operations. She joined Kai in February 2005. Prior to Relypsa, Ms. Ball was an independent consultant from June 2011 to October 2012, advising start-up life science companies on various strategic and operational business matters. She served as Chief Financial Officer and Senior Vice President of Finance and Administration of KAI Pharmaceuticals, Inc. from February 2005 to January 2011, where she was responsible for finance, administration and strategic planning and was involved in a venture capital financing, pharmaceutical partnerships and as a consultant, KAI’s acquisition. She served as Vice President of Finance at KAI Pharmaceuticals since March 2005 and also served as its Vice President of Administration. At KAI, she was responsible for finance, administration and strategic planning, led a 35 million round of venture financing and was a key member of the deal teams responsible for two pharmaceutical partnerships and the Amgen acquisition. Previously, she served as Vice President of Finance at Exelixis, Inc. from 2000 to 2005, where she was involved in four acquisitions and Exelixis’ initial public offering and other financings. She served as Chief Financial Officer and Controller at Exelixis, Inc. While at Exelixis, Ms. Ball served as Interim Chief Financial Officer from 2003 to 2004, was highly involved in several acquisitions, was involved in raising in equity financings and debt and managed the day-to-day finance, accounting and SEC compliance activities. Prior to Exelixis, Ms. Ball served as a Senior Manager at the accounting firm Ernst & Young LLP, where she served both emerging growth and multinational companies in the high technology and life sciences fields. She obtained extensive experience in many areas including mergers and acquisitions, spin-offs, initial public offerings, in-licensing, collaborations, technical accounting and financial regulatory agency reporting. She had been a Director of Forty Seven Inc. since February 2018 until 2020. Ms. Ball is a Certified Public Accountant. She holds a B.S. in Accounting from Babson College.
Positions
- Company NameOruka Therapeutics, Inc.Stock CodeORKAPositionIndependent DirectorColleagues
- LOLawrence Otto KleinPresident, CEO & Director
- SKSamarth KulkarniIndependent Chairman of Board
- PTPaul T. QuinlanGeneral Counsel & Secretary
- JGJoana GoncalvesChief Medical Officer
- AAArjun AgarwalSenior VP of Finance & Treasurer
- LSLaura SandlerChief Operating Officer
- PEPeter Evan HarwinIndependent Director
- ABAndrew BlauveltChairman of Scientific Advisory Board
